Relationship leverages Quest’s sequencing and specimen collection expertise with Scipher’s precision medicine technology SECAUCUS, NJ and WALTHAM, MA – November 28, 2023 – Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services,...
WALTHAM, Mass., September 7, 2023 – Scipher Medicine Corporation, a precision immunology company matching each patient with their most effective therapy, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC), and Centers for Medicare and...
Focus on development of precision therapeutics could lead to new and more effective treatments in disease areas including cardiovascular and CNS WALTHAM, Mass.–(July 17, 2023, BUSINESS WIRE)–Scipher Medicine today announced that it has entered into a...
First-of-its-kind technology stack in autoimmune diseases. Provides unprecedented insights into optimal patient treatment pathway. WALTHAM, Mass. (January 10, 2023) – ScipherMedicine, a precision immunology company matching each patient with their most effective...
Patients Were 3.1x More Likely to Reach Treatment Goals When Tested with PrismRA® Demonstrates Significantly Superior Outcomes Compared to Standard of Care in 3,348 Patient Analysis WALTHAM, Mass. (November 10, 2022) – Scipher Medicine announced data validating...
Collaboration Achieves Key Milestones After Preclinical Validation Work, Triggers Milestone Payment to Scipher WALTHAM, Mass. (May 24, 2022) – Scipher Medicine today announced that Galapagos (Euronext & NASDAQ: GLPG) has exercised its option to in-license...
